Climb Bio, Inc. Common Stock (CLYM) is a publicly traded Healthcare sector company. As of September 17, 2026, CLYM trades at $14.08 with a market cap of $810.43M and a P/E ratio of -15.89. CLYM moved -0.35% today. Year to date, CLYM is +274.93%; over the trailing twelve months it is +563.21%. Its 52-week range spans $1.05 to $18.33. Analyst consensus is strong buy with an average price target of $28.11. Rallies surfaces CLYM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for CLYM, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $14.08 |
| Market Cap | $810.43M |
| P/E Ratio | -15.89 |
| EPS | $-0.88 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.33 |
| 52-Week Low | $1.05 |
| Volume | 803.27K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-59.85M |
| Gross Margin | 0.00% |
12 analysts cover CLYM: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.11.